Multimodal imaging, including traditional and newer techniques, is necessary for identifying the spectrum of retinal lesions associated with age-related macular degeneration (AMD), said David Sarraf, MD.
Earlier this month, a jury convicted West Palm Beach retina surgeon Solomon Melgen, MD, on 67 counts of Medicare fraud. This high-profile case hit very close to home, as myself and another retina specialist from my own community were on opposing sides of the case.
Nucleoside-reverse, transcriptase inhibitors (NRTIs) or their derivatives could one day be used to prevent or treat age-related macular degeneration (AMD), according to Jayakrishna Ambati, MD.
Ophthalmologists were asked what their plans were for using OCT angiography. You can participate in the survey and gain access to the full survey results by visiting www.practice-scope.com/#register.
Many investigational drugs under development for the treatment of neovascular age-related macular degeneration (nvAMD) have advanced into the clinical trial stage, including several that are being evaluated in pivotal trials, said Peter K. Kaiser, MD.
Patients with a history of frequent anti-vascular endothelial growth factor (anti-VEGF) injections for the treatment of age-related macular degeneration (AMD) may not be the best potential candidates for encapsulated cell technology (ECT).
In a placebo-controlled, dose-finding, proof-of-concept study conducted in patients with geographic atrophy secondary to age-related macular degeneration, an anti-amyloid β monoclonal antibody (GSK933776, GlaxoSmithKline) was safe and well-tolerated, but did not meet primary or secondary efficacy endpoints.
Treat-and-extend approach for neovascular AMD leads to beneficial results in 2-year clinical trial.
The recent FDA clearance of a swept-source optical coherence tomography (OCT) and OCT angiography (OCTA) platform (PLEX Elite 9000, Carl Zeiss Meditec) for posterior ocular structures enables fast, dense, wide, and deep imaging of the retina, choroid, and their associated microvasculature, said Philip J. Rosenfeld, MD, PhD.
AIVITA Biomedical has successfully engineered a three-dimensional transplantable retina construct and demonstrated connectivity and conductivity in an animal model of retinal degeneration.